Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, Follicular 2Hypertension 2

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Amlodipine × Clear all
NCT06236061 2026-01-13

Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy

Novartis

Phase 3 Completed
718 enrolled
Lymphoid

Hypertension, Lymphoma, Follicular

NCT02072330 2014-02-26

Study to Evaluate the Efficacy and Safety of Combined Administration of TAK-536CCB and Hydrochlorothiazide in Patients With Grade I or II Essential Hypertension.

Takeda

Phase 2/3 Completed
353 enrolled
Lymphoid

Hypertension, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡